



Transferosomes: Novel Delivery System for Increasing The skin Permeation of Drugs

Tomy Muringayil Joseph, P. Mereena Luke

Polymers Technology Department, Chemical Faculty, Gdansk University of Technology, 80-233 Gdansk, Poland.

ABSTRACT

The use of vesicular carriers has recently emerged as a feasible method for minimizing the obstructive effects of the stratum corneum. The use of transferosomes, also known as ultra-deformable lipids or elastic liposomes, in cutaneous distribution has attracted a lot of attention. They are generally used to treat a range of chronic skin disorders, but they may also be utilised to guarantee patient compliance via concentrated and controlled distribution. These self-assembled nanocarriers may adjust their pore size to that of the stratum corneum. Edge activators (specific surfactants), phospholipids, buffering agents, and other substances are found in transferosomes. Due to the activity of edge activators and their concentration, constructed vesicles have the requisite flexibility. Drug solubilization, efficient drug loading, and therapeutic molecule permeability may all be improved by elastic liposomes. As nanocarriers, transferosomes have improved reflectivity and provide a diverse platform for effective transdermal applications. These one-of-a-kind nanocarriers also have exceptional elasticity and penetration. These systems are thought to be safe, with effective delivery routes for pharmaceutically and aesthetically active chemical moieties. Recent scientific results highlighting the need for ultra-deformable liposomes have revealed that medication penetration is constant and effective. This book contains up-to-date research as well as in-depth updates on crucial issues and the usage of future transferosomes with enhanced bioavailability profiles.

Key Words: Transferosomes, Transdermal delivery, Bioavailability, Self-assembled, Skin permeation, Ultra-deformable vesicles

INTRODUCTION

The term 'transferosome' is derived from the Latin words 'transferre,' which means 'to carry over,' and 'soma,' which means 'body.' A transferosome (Figure 1) is a synthetic vesicle with properties comparable to those of a cell vesicle or a cell in exocytosis, making it appropriate for regulated and perhaps targeted drug delivery. In 1991, Gregor Cevc proposed the fundamental concept of a transferosome. [1] A transferosome is a highly adaptive and stress-responsive complex aggregation. It's a vesicle with an aqueous centre and a complicated lipid bilayer surrounding it. Because the local composition and form of the bilayer are interrelated, the vesicle is self-regulating and self-optimizing. This enables the transferosome to easily navigate various transport barriers. [2] The transferosomal drug delivery method acts as a drug carrier for non-invasive targeted drug administration and therapeutic agent sustained release, making medicine administration simple and safe. Avoiding first-pass




Figure 1: Structural representation of one transferosome unit.

metabolism, predictable and extended activity duration, the utility of short-half-life drugs, improving physiological and pharmacological response, minimising undesirable side effects, avoiding drug level fluctuations, inter-patient and

Corresponding Author:

Tomy Muringayil Joseph, Polymers Technology Department, Chemical Faculty, Gdansk University of Technology, 80-233 Gdansk, Poland.

ISSN: 2231-2188 (Print)

ISSN: 2231-685X (Online)

Received: 04.01.2020

Revised: 05.02.2020

Accepted: 08.03.2020

Published: 05.08.2020

intra-patient variations, and mosaic delivery are all potential advantages of the transfersosomal drug delivery system over traditional routes. [3]

Transfersomes were developed to employ phospholipid vesicles as a transdermal drug carrier. With their ultra-flexible membranes, these self-optimized aggregates may safely and effectively deliver medication into or through the skin, depending on the administration or application technique. By pressing themselves along the stratum corneum's intracellular sealing lipid, transfersomes get over the barrier to skin penetration. [4] This is achievable because to the high vesicle deformability, which allows for self-adapting entry in response to mechanical force from the environment. The resulting flexibility of the transfersome membrane decreases the risk of complete vesicle rupture in the skin and allows transfersomes to follow the natural water gradient across the epidermis when used under nonocclusive settings. Transfersomes may pass through the intact stratum corneum through two intracellular lipid routes with differing bilayer properties. [5] The self-optimizing deformability of traditional composite transfersomes membrane reacts to ambient stress when pressed against or lured into a microscopic opening, enabling ultra-deformable transfersomes (Figure 2) to change their membrane composition locally and reversibly. The transfersome components that can resist large membrane deformation concentrate in high-stress areas, whereas the less adaptable molecules are diluted. This lowers the energy cost of membrane deformation, enabling the ultra-flexible particles that arise to enter and flow through holes swiftly and efficiently. [6]




Figure 2: Structure of deformed Transfersome.

HUMAN SKIN - ANATOMY AND PHYSIOLOGY

The skin is a critical organ that covers the whole of the human body's exterior surface and serves as a protective barrier between internal organs and the environment. The skin is a dynamic organ that changes over time as outer layers are shed and internal layers are replaced. The thickness of a person's skin varies depending on their anatomical position, gender, and age. [7] The skin is continuous, and the mucous membranes line the body's surface. An typical adult's skin covers around 2 m² and absorbs about a third of the blood that circulates through the body, as well as acting as a permeability barrier against the transdermal absorption of a variety of chemical and biological substances. Between the underlying blood circulation network and the outside environment, the skin serves as a barrier. [8] It defends against hazards such as physical, chemical, and microbiological. It acts as a thermostat to keep the body temperature stable. It assists in the regulation of blood pressure and protects the human body from the harmful effects of UV rays. The skin plays a big role in medication permeation and absorption via the dermis. [9]

The structure of the skin is indicated by three distinct layers:

- The epidermis is the skin's outermost layer, which serves as a waterproof barrier and determines the color of our skin.
- The dermis, which lies under the epidermis and comprises tough connective tissue, hair follicles, and sweat glands, is located beneath the epidermis.
- The hypodermis (deeper subcutaneous tissue) is made up of fat and connective tissue.

The epidermis is largely made up of surface ectoderm, but it also contains melanocytes from the neural crest, antigen-processing Langerhans cells from the bone marrow, and pressure-sensing Merkel cells from the neural crest. The dermis, which is largely made up of mesoderm, is made up of collagen, elastic fibres, blood vessels, sensory structures, and fibroblasts (Figure 3). [10]




Figure 3: Schematic presentation of human skin.

Subcutaneous fat layer

The hypodermis, often known as the subcutaneous fat layer, links the dermis to the body's underlying parts. Most regions of the body have a thick coating of this layer, which is several centimetres thick. This layer of adipose tissue's principal role is to insulate the body and provide mechanical protection against physical stress. The subcutaneous adipose layer, which may potentially provide a fast supply of high-energy molecules, delivers the major blood vessels and nerves to the skin. [11]

Dermis

The dermis contains blood and lymphatic vessels, nerve endings, pilosebaceous units such as hair follicles and sebaceous glands, and sweat glands such as eccrine and apocrine. It provides physiological support to the epidermis and makes up the majority of human skin. In terms of transdermal drug delivery, this layer is generally characterised as merely gelled water, and hence poses a minor barrier to most polar medications, but the dermal barrier should be addressed when administering highly lipophilic substances. [12]

Epidermis

Ten to twenty layers of cells make up the epidermis. This pluristratified epithelium also contains melanocytes, which play a role in skin pigmentation, and Langerhans' cells, which play a function in antigen presentation and immunological responses. The epidermis, like any epithelium, receives sustenance from the dermal vascular network. The epidermis is separated into many layers. The stratum germinativum is the epidermis's most fundamental layer. The layers above the base layer are the stratum spinosum, stratum granulosum, stratum lucidum, and stratum corneum. [13]

Stratum Corneum

The stratum corneum is a multilayer stratum of non-nucleated, flat, polyhedral-shaped, 2–3 μm thick corneocytes that is 10–20 μm thick. Corneocytes are made up mostly of insoluble bundled keratins wrapped in a cell envelope kept together by cross-linked proteins and covalently connected lipids. Corneodesmosomes are membrane junctions that connect corneocytes and aid in the stability of the stratum corneum. [14] Exocytosis of lamellar structures during keratinocyte terminal development provides the majority of the lipids that make up the intercellular space between corneocytes. These lipids are required to keep the epidermal barrier healthy. The stratum corneum is the skin's primary barrier against penetration and permeability. The skin can be thought of as a bilaminated membrane in the most basic sense, with a penetrating molecule passing through the lipophilic stratum corneum as well as the aqueous environment of the underlying viable epidermis and upper dermis to reach the

dermal vasculature and rapid systemic distribution. [15]

MATERIALS EMPLOYED

In the formulation of transferosomes, phospholipids, surfactants, alcohol, colour, buffering agent, and other ingredients are often used. Soya phosphatidylcholine, egg phosphatidylcholine, dipalmitoylphosphatidylcholine, and other phospholipids are employed as vesicles-forming agents. Sodium cholate, sodium deoxycholate, Tween-80, Span-80, and other surfactants are utilized to provide flexibility. Solvents such as ethanol or methanol may be used. A saline phosphate buffer is used as the hydration medium (pH 6.4). [16]

FEATURES OF TRANSFEROSOMES

Transferosomes feature a structure that combines both hydrophobic and hydrophilic moieties, enabling them to accept a wide range of solubility in pharmaceutical compounds. Transferosomes may bend and pass through constrictions 5 to 10 times smaller than their own diameter without losing any function. This high deformability makes it easier for intact vesicles to enter. They may carry drugs with low and large molecular weights, including as analgesics, anaesthetics, corticosteroids, sex hormone, anticancer, insulin, gap junction protein, and albumin. [17] They are biocompatible and biodegradable, similar to liposomes, since they are made of natural phospholipids. They have a high entrapment efficiency, which in the case of lipophilic medicines might reach 90%. They keep the drug enclosed from being broken down by the body's metabolism. [18]

ADVANTAGES OF TRANSFEROSOMES[19]

- Transferosomes can deform and pass through narrow constriction without measurable loss.
- They have a high entrapment efficiency, reaching up to 90% for lipophilic medicines.
- Because of its high deformability, intact vesicles may be pierced more efficiently.
- They can carry analgesics, anesthetics, corticosteroids, sex hormones, anticancer drugs, insulin, gap junction protein, and albumin, among other pharmaceuticals with low and high molecular weights.
- Transferosomes feature a structure that blends hydrophobic and hydrophilic moieties, enabling them to receive a wide range of solubility therapeutic compounds. They act as a storage facility, slowly releasing their contents.

- They are biocompatible and biodegradable, similar to liposomes, since they are made of natural phospholipids.
- They keep the drug enclosed from being broken down by the body's metabolism.
- Scalability is simple since the approach is simple and does not need the use of pharmaceutically unwanted substances.

LIMITATIONS OF TRANSFEROSOMES [20]

- Transferosomes are chemically unstable due to their tendency for oxidative degradation.
- The purity of natural phospholipids is another aspect that works against the utilization of transferosomes as drug delivery vehicles.
- The cost of transferosome formulations is prohibitively expensive.

PREPARATION OF TRANSFEROSOMES

There are a variety of patented and published techniques for making transferosomes. Phosphatidylcholine is usually combined with sodium cholate or another suitable surfactant in ethanol. Among the most popular approaches are:

Suspension Homogenization Process

In this method, ethanolic soybean phosphatidylcholine is mixed with a sufficient amount of edge activators, such as sodium cholate. This suspension is mixed with a Triethanolamine-HCl buffer solution to get a total lipid concentration, then sonicated, frozen, and thawed for 2 to 3 times before being brought to the desired size, which is measured by photon correlation spectroscopy. The water is sterilised by passing it through a 0.2 mm micro porosity filter. A dynamic light scattering technique is used to validate the final vesicle size. [21]

Reverse Phase Evaporation Method

In this process, lipids dissolved in organic solvents are put in a round bottom flask. An aqueous media containing edge activators is supplied during nitrogen purging. The drug may be delivered to a lipid or aqueous solution depending on its solubility qualities. The system is then sonicated until it creates a homogeneous dispersion that does not separate for at least 30 minutes. The organic solvent is subsequently extracted at reduced pressure. Following that, the solution will transition into a thick gel, which will be followed by the formation of vesicles. Non-encapsulated material and leftover solvents may be removed using dialysis or centrifugation (Figure 4). [22]




Figure 4: Reverse Phase Evaporation Method.

Rotary Film Evaporation Method

Bangham was the first to develop the revolving film evaporator process, sometimes known as handshaking. This technique necessitates the use of phospholipids and surfactants in order to form a thin layer. A phospholipid and ethanol solution is constructed in a combination of crude solvents such as chloroform and methanol. In the study of multilamellar vesicles, this method is often used. The solution is then transferred to a flask with a circular bottom and rotated at a constant temperature and pressure (higher than the glass transition temperature of lipids). On the flask's walls, a coating of lipids and edge activators develops. The lipids in the twisted film stretch and form bilayer vesicles after being hydrated with an aqueous media containing medicine. To make vesicles of the right size, the superior vesicles might be sonicated or extruded. [23]

Modified Handshaking Process

This approach is also known as the lipid film hydration technique. In a 1:1 ratio, ethanol and chloroform are mixed. This pharmacological combination dissolves lipids and edge activators. Evaporation is used to get rid of the solvent. At temperatures above the liquid transition point (43°C), handshakes are conceivable. As a consequence of the constant rotation, a thin lipid coating develops on the flask wall. To enable the solvent to fully evaporate, the preparation is left overnight. The film is hydrated for 15 minutes with phosphate buffer and gently shaken at the suitable temperature (Figure 5). [24]




Figure 5: Rotary Film Evaporation Method/ Modified Hand Shaking Method.

Thin Film Hydration Technique

This approach is classified into three steps:

1. An organic solvent is used to dissolve a thin layer of vesicle phospholipids and surfactants (such as chloroform or methanol). Heating occurs at a temperature higher than the lipid's transition temperature. To release the organic solvent combination, the method is carried out in a rotary evaporator. Any solvent remains are removed overnight by vacuuming.
2. Using a suitable buffer, the produced film is hydrated for one hour at 60 RPM. At room temperature, the vesicles are allowed to grow for 2 hours.
3. Prepare small vesicles by sonicating prepared vesicles for 30 minutes at 50°C or at room temperature in a bath sonicator. Sonication is done for 30 minutes at 40°C while utilizing a probe sonicator. A sandwich layer of 200 nm – 100 nm is generated by manually extruding the sonicated vesicles 10 times through a polycarbonate membrane.

Ethanol Injection Method

The medication-containing aqueous solution is kept at a constant temperature by constant stirring. Drops of edge activators are introduced into the aqueous solution, along with an ethanolic phospholipid solution. The lipid molecules precipitate and form bilayered structures when the aqueous media comes into contact with the solution. When compared to other methods, the process is easy to scale up, simple to use, and highly repeatable, offering a variety of benefits (Figure 6). [26]




Figure 6: Ethanol Injection Method.

Freeze-Thaw Method

This method includes exposure to both low and high temperatures. The multilamellar vesicles are first frozen and then heated to very high temperatures. The prepared suspension is submerged in a nitrogen bath after being transferred to a tube at 30°C for 30 seconds. They are then treated to high temperatures in a water bath after they have been frozen. This procedure is repeated eight to nine times (Figure 7). [27]




Figure 7: Freeze-Thaw Method.

Vortexing/ Sonication Method

Phosphate buffer is used to integrate the mixed lipids (edge activators, phosphatidylcholine, and medicinal medicines). After that, it's vortexed to make a milky suspension. The suspension undergoes sonication before being extruded via polycarbonate membranes (Figure 8). [28]




Figure 8: Vortexing / Sonication Method.

OPTIMIZATION OF FORMULATION CONTAINING TRANSFEROSOMES

A variety of procedural variables may influence the transfersomes' preparation and quality. As a consequence, the process for preparing the food was enhanced and validated. The manufacturing method for the formulation determines the process variables. [29] The following are critical process elements in the production of transfersomes:

1. The lecithin-to-surfactant ratio
2. The effect of various solvents
3. The effect of various surfactants
4. A hydration medium

The medication's entrapment efficiency was picked for optimization. Through the creation of a particular system, the other factors were kept constant.

MECHANISM OF ACTION OF TRANSFEROSOMES

A single amphipathic polymer, such as phosphatidylcholine, forms the carrier aggregate, which self-assembles into a lipid bilayer in aqueous solvents and closes into a simple lipid vesicle. A bilayer softening component, such as a biocompatible surfactant or an amphiphile medicine, improves lipid bilayer flexibility and permeability. The resulting transferosome vesicle may simply and swiftly adjust its shape to the environment by matching the local concentration of each bilayer component to the local tension faced by the bilayer. [30] The artificial membrane of the transferosome distinguishes it from other vesicles because it is softer, more flexible, and more variable. High bilayer deformability in transferosomes has a positive effect on their ability to bind and retain water. A highly deformable and hydrophilic vesicle will strive to avoid dehydration at all costs; this may involve a transport mechanism comparable to but not identical to forward osmosis. [31] A transferosome vesicle put on an open biological surface, such as non-occluded skin, crosses the barrier and migrates into the water-rich deeper layers to ensure adequate hydration. Barrier penetration needs reversible bilayer deformation, yet the integrity of the vesicle or barrier properties must not be threatened in order for the underlying hydration affinity and gradient to remain in place. Because the transferosome is too large to distribute through the skin, it must find and force its own way into the organ. The transferosome vesicles enhance the carrier's ability to widen and overcome the hydrophilic pores in the epidermis or another barrier (e.g. the plant cuticle). Because the agent is gradually released from the drug carrier, the drug molecules may scatter and adhere to their target. Unless the vesicle is actively taken up by the cell in a process known as endocytosis, drug delivery to an intracellular action site may also include the carrier's lipid bilayer fusion with the cell membrane (Figure 9) [33].




Figure 9: Interaction of transferosomes with skin tissue.

CHARACTERIZATION OF TRANSFEROSOMES [34-36]

Liposomes, niosomes, and micelles are all used to describe transferosomes. The following characterization criteria for transferosomes must be addressed.

1. Vesicle size distribution and zeta potential

The Dynamic Light Scattering device from Malvern Zetasizer was used to assess vesicle size, size distribution, and zeta potential.

2. Vesicle morphology

To determine vesicle diameter, photon correlation spectroscopy or the dynamic light scattering (DLS) method may be utilised. Samples were made in distilled water, filtered via a 0.2 mm membrane filter, and diluted with filtered saline for photon correlation spectroscopy or dynamic light scattering (DLS) experiments. Transferosome vesicles may be seen via TEM, phase contrast microscopy, and other methods. Vesicle stability may be estimated by tracking the size and form of vesicles over time. DLS searches for structural changes, while TEM looks for mean size.

3. Number of vesicles per cubic mm

This is a critical component for optimizing the composition of the process and other elements. Non-sonicated transferosome formulations are diluted five times in a 0.9 percent sodium chloride solution. A hemocytometer and an optical microscope may be used for further study. The Transferosomes in 80 small squares are counted and calculated using the following formula:

Total number of Transferosomes per cubic mm = (Total number of Transferosomes counted $\times$ dilution factor $\times$ 4000) / Total number of squares counted

4. Entrapment efficiency

Entrapment efficiency is calculated using the percentage entrapment of the medicament added. The untrapped medicine was separated using a mini-column centrifugation method to determine the entrapment efficiency. After centrifugation, the vesicles were burst with 0.1 percent Triton X-100 or 50 percent n-propanol. The entrapment efficiency is expressed as:

Entrapment efficiency = (Amount entrapped / Total amount added) $\times$ 100

5. Drug content

The drug content may be assessed using one of the instrumental analytical techniques, such as modified high-performance liquid chromatography method (HPLC) with a UV detector, column oven, auto sample, pump, and computerized analysis

software, depending on the pharmacopoeia drug's analytical method.

6. Turbidity measurement

The turbidity of medicine in an aqueous solution may be determined using a nephelometer.

7. Degree of deformability or permeability measurement

One of the most important and distinctive characteristics for the characterization of transferosomes is permeability study. Pure water is used as a control in the deformability test. Transferosomes are prepared by filtering them through a large number of pores of varying sizes. After each pass, dynamic light scattering (DLS) measurements are taken to record particle size and size distributions.

8. Penetration ability

The ability of Transferosomes to penetrate may be assessed using fluorescence microscopy.

9. Occlusion effect

Occlusion of the skin is supposed to promote medication penetration in traditional topical therapies. Elastic vesicles, on the other hand, have a similar issue. The hydrotaxis of water is the primary driving force for vesicle penetration through the skin, from its relatively dry surface to its water-rich deeper layers. Because it prevents water from evaporating from the skin, occlusion has an influence on hydration forces.

10. Surface charge and charge density

Transferosomes' surface charge and charge density may be determined using Zetasizer.

11. In vitro drug release

In vitro medication release study is used to calculate the penetration rate. The time necessary to establish steady-state permeation and the permeation flux at a steady-state, as well as information from in vitro experiments, are used to optimize the formulation before more expensive in vivo research. For measuring drug release, transferosome suspension is incubated at 37°C for many hours, and samples are taken at different times, with the free drug separated by microcolumn centrifugation. The amount of drug released is then calculated indirectly, beginning with the initial amount of drug entrapped.

12. In vitro Skin permeation Studies

A modified Franz diffusion cell with a receiver compartment capacity of 50 ml and an effective diffusion area of 2.50 cm² was used in this study. In vitro drug study was carried out using goat skin in a phosphate buffer solution (pH 7.4).

The penetration experiments were conducted using fresh goat abdomen skin purchased from the slaughterhouse. After the hairs on the abdomen were removed, the skin was moisturised with a standard saline solution. The adipose tissue layer was removed by rubbing the skin's adipose tissue layer with a cotton swab. The skin was maintained at 0-40°C in an isopropyl alcohol solution. The treated skin was placed horizontally atop the receptor compartment of the Franz diffusion cell, with the stratum corneum side looking upwards toward the donor compartment. The effective penetration area from the donor compartment to the receptor compartment was 2.50cm², and the receptor compartment had a capacity of 50 ml. A magnetic bar was used to swirl 50 ml of phosphate-buffered saline (pH 7.4) into the receptor compartment at 100RPM. The formulation was applied to the skin (equivalent to 10 mg of medicine), and the diffusion cell's top was covered. 1 ml aliquots of the receptor medium were taken at regular intervals and replaced with an equal quantity of fresh phosphate buffers to maintain sink conditions (pH 7.4). Correction factors were used to compute the release profile for each aliquot. The materials were examined using any instrumental analytical approach.

13. Physical stability

The original quantity of medication entrapped in the formulation was determined, and it was preserved in sealed glass ampoules. The ampoules were stored at 4 ± 2°C, 25 ± 2°C, and 37 ± 2°C for at least three months. Samples from each ampoule were analyzed after 30 days to check whether there was any pharmaceutical leaking. By keeping the original drug entrapment at 100%, the percent drug loss was calculated.

APPLICATIONS OF TRANSFEROSOMES [37-38]

1. Delivery of insulin

Transferosomes have shown to be a practical means of non-invasively transferring large molecular weight drugs to the skin. Insulin is normally administered by a subcutaneous injection, which is inconvenient. All of these problems are solved by encapsulating insulin in transferosomes (transfersulin). Depending on the carrier composition, the first indication of systemic hypoglycemia emerges 90 to 180 minutes after Transfersulin injection on undamaged skin.

2. Delivery of corticosteroids

Transferosomes have also been used to administer corticosteroids. Transferosomes improve the site-specificity and overall drug safety of corticosteroid injection into the skin by modifying the epicutaneously administered medicine dose. Transferosome-based corticosteroids are

physiologically active at far lower levels than those currently utilized to treat skin diseases.

3. Delivery of proteins and peptides

Transferosomes have been used to transport proteins and peptides for a long time. Proteins and peptides are large biogenic molecules that are difficult to absorb and are completely destroyed in the digestive system when consumed orally. These are the reasons why these peptides and proteins need to be injected into the body in the first place. A number of solutions have been devised to help alleviate the situation. The bioavailability of transferosomes is equivalent to the bioavailability of a subcutaneous injection of the same protein solution. A significant immunological response was generated after repeated epicutaneous injections of transferosomal preparations of this protein.

4. Delivery of interferons

Transferosomes have been shown to carry interferons such as leukocytic produced interferon- ($\text{INF-}\alpha$). $\text{INF-}\alpha$ is an antiviral, antiproliferative, and immunomodulatory protein that occurs naturally. When utilized as drug delivery vehicles, transferosomes have the potential to provide controlled drug release and boost the stability of labile medications. For prospective transdermal usage, researchers looked into the composition of transferosomes including interleukin-2 and interferon- α . Transferosome-trapped IL-2 and $\text{INF-}\alpha$ were shown to be supplied in sufficient amounts for immunotherapy.

5. Delivery of Anticancer

Transdermal delivery of anti-cancer drugs like methotrexate was explored utilizing transferosome technology. The results were favorable. This offers a unique treatment approach, especially for skin cancer.

6. Delivery of anesthetics

Under the correct conditions, the administration of anaesthetics in the suspension of highly deformable vesicles, transferosomes, gives topical anaesthesia in less than 10 minutes. The highest level of pain insensitivity is comparable to that of a subcutaneous bolus injection (80%), although transferosomal anaesthetics have a longer duration of effect.

7. Delivery of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

The use of non-steroidal anti-inflammatory drugs (NSAIDs) has been related to a number of gastrointestinal side effects. These problems might be solved by delivering ultra-deformable vesicles through transdermal distribution. Both Diclofenac and Ketoprofen have been studied in the past. The commercialization of ketoprofen in a Transferosome formulation was authorized by Swiss regulatory authorities

in 2007, and the pharmaceutical will be marketed under the brand name Diractin.

8. Delivery of Herbal Drugs

Transferosomes may infiltrate the stratum corneum and deliver nutrients to the skin on a local level, enabling it to continue to function. Capsaicin Transferosomes have been produced in this area, and they show improved topical absorption as compared to pure capsaicin.

9. Applications in cosmetics

Cosmetics demand is gradually rising throughout the world as people seek to improve their appearance and avoid skin damage. Cosmeceutical products enhance one's look while also delivering medicinal benefits (Figure 10).




Figure 10: Transferosomes' applications in cosmetic technology.

CONCLUSION

The transdermal route has long been the favoured mode of medicine administration due to its distinct and diverse features. The stratum corneum's impermeability, on the other hand, poses a severe difficulty for transdermal medication delivery since it acts as a complete barrier to drug penetration. As a consequence, the effective delivery of hydrophilic and hydrophobic drugs, as well as amphiphilic compounds, is emphasized by the transferosomal system. Transferosomes are an appropriate and excellent technology because of their decreased dose frequency, more efficacy, greater loading capacity, and larger topical applications, as well as greater stability features. Transferosomes have a bright future as a site-specific delivery system for active medicines, as well as in a number of cosmetic applications. In terms of oxidative degradation, purity, and retention quality, there are still a few concerns to iron out. As a consequence, future process enhancements will need special considerations and technological advancements. In order to promote the future possibilities of these endowed nanocarriers, breakthroughs in the synergistic potential of components and active chemicals must be investigated internationally. It's also worth emphasizing that, prior to industrial scale-up, significant study based on compelling preclinical and clinical

examinations is required to get the data needed to establish the safety of challenging medications. Novel transferosomes will most likely focus on improved treatment regimens using more complex, promising, and well-organized new approaches, which will necessitate improvements in scientific perspectives. In order to mitigate the current drawbacks of transferosomes, it is also necessary to investigate innovative medicinal excipients with additional features. In the future, industrial pharmaceutical companies may investigate new prospects for key developmental qualities of properly designed transferosomes.

ACKNOWLEDGEMENT

The author acknowledges the college management, principal, teachers, non-teaching staffs, and colleagues for their kind support.

CONFLICT OF INTEREST

The authors declare no Conflict of Interest regarding the publication of the article.

FUNDING INFORMATION

No funding agency is acknowledged.

REFERENCES

- Benson HA. Transferosomes for transdermal drug delivery. *Exp Opin Drug Deliv*. 2006;3(6):727-37.
- Ghai I, Chaudhary H, Ghai S, Kohli K, Kr V. A Review of Transdermal Drug Delivery Using Nano-Vesicular Carriers: Transferosomes. *Recent Pat Nanomed*. 2012;2(2):164-71.
- Rai K, Gupta Y, Jain A, Jain SK. Transferosomes: self-optimizing carriers for bioactives. *PDA J Pharm Sci Technol*. 2008;62(5):362-79.
- Chauhan N, Kumar K, Pant NC. An updated review on transferosomes: a novel vesicular system for transdermal drug delivery. *Univers J Pharm Res*. 2017;2(4):49-52.
- Garg V, Singh H, Bimbrawh S, Kumar Singh S, Gulati M, Vaidya Y, Kaur P. Ethosomes and transferosomes: principles, perspectives and practices. *Curr Drug Deliv*. 2017;14(5):613-33.
- Opatha SA, Titapiwatanakun V, Chutoprapat R. Transferosomes: A promising nanoencapsulation technique for transdermal drug delivery. *Pharmaceutics*. 2020;12(9):855.
- Sharma U, Verma P, Jain NK. A Review on Novel Vesicular Drug Delivery System: Transferosomes. *Int J Pharm Life Sci*. 2020;11(7):6812-24.
- Priyanka K, Singh S. A review on skin targeted delivery of bioactives as ultradeformable vesicles: overcoming the penetration problem. *Curr Drug Targ*. 2014;15(2):184-98.
- Chaurasiya P, Ganju E, Upmanyu N, Ray SK, Jain P. Transferosomes: a novel technique for transdermal drug delivery. *J Drug Deliv Therapeut*. 2019;9(1):279-85.
- Solanki D, Kushwah L, Motiwale M, Chouhan V. Transferosomes-A Review. *World J Pharm Pharm Sci*. 2016;5:435-49.
- Jain AK, Kumar F. Transferosomes: Ultradeformable vesicles for transdermal drug delivery. *Asian J Biomater Res*. 2017;3:1-13.
- Sarmah PJ, Kalita B, Sharma AK. Transferosomes based transdermal drug delivery: an overview. *Int J Adv Pharm Res*. 2013;4(12):2555-63.
- Steven B.Hoath, D.G.Leahy, The Organization of Human Epidermis: Functional Epidermal Units and Phi Proportionality, *Journal of Investigative Dermatology*, 121(6), December 2003: 1440-1446.
- Bhokare B. Transferosomes: A Novel Drug Delivery System. *Int J Res EngAppl Sci*. 2017;7:190-4.
- Sachan R, Parashar T, Singh V, Singh G, Tyagi S, Patel C, Gupta A. Drug carrier transferosomes: a novel tool for transdermal drug delivery system. *Int J Res Devel Pharm Life Sci*. 2013;2(2):309-16.
- Eldhose MP, Mathew F, Mathew NJ. Transferosomes-a review. *Int J Pharm Pharm Res*. 2016;6:436-52.
- Kaur N. Transdermal Drug Delivery Through Carriers: Transferosomes. *PharmaTutor*. 2014;2(12):77-85.
- Jangme CM, Chavan DV. A review on transferosome: is a boon to human life. *Int Res J Pharm Appl Sci*. 2013;3(2):174-9.
- Madhumitha V, Sangeetha S. Transferosomes: A Novel Vesicular Drug Delivery System for Enhanced Permeation through Skin. *Res J Pharm Technol*. 2020;13(5):2493-501.
- Veldurthi R, Sailaja AK. A Review on Transferosomes as Ultra Deformable Vesicular Carriers for Transdermal Drug Delivery. *InnovatInt J Med Pharm Sci*. 2017;2(5):48-56.
- Bera P, Upamanyu N, Jaiswal J. Transferosomes and Ethosomes: Nano Carriers and their Clinical Potential in Transdermal Drug Delivery System. *Int J Pharm SciNanotechnol*. 2020;13(2):4793-807.
- Kumavat SD, Chaudhari YS, Borole P, Duvvuri P, Bubera N, Shenghani K, Shah P, Mishra P. Transferosomes: a promising approach for Transdermal drug delivery system. *Asian J Pharm Sci Res*. 2013;3(5):1-7.
- Bhardwaj V, Shukla V, Singh A, Malviya R, Sharma PK. Transferosomes ultra flexible vesicles for transdermal delivery. *Int J Pharm Sci Res*. 2010;1(3):12-20.
- Piumitali B, Neeraj U, Jyotivardhan J. Transferosomes—A Nanoscience in Transdermal Drug Delivery and Its Clinical Advancements. *Int J Nanosci*. 2020;19(04):1950033.
- Sivannarayana P, Rani AP, Saikishore V, VenuBabu C, SriRekha V. Transferosomes: Ultra deformable vesicular carrier systems in transdermal drug delivery system. *Res J Pharm Dosage Form Technol*. 2012;4(5):243-55.
- Chandran SM, Jaghatha T, Wesley J, Remya SB, Aparna P. A Review on Transferosomes. *Indo Am J Pharm Sci*. 2018;5(4):2405-11.
- Kumar A. Transferosome: a recent approach for transdermal drug delivery. *J Drug Deliv Therapeut*. 2018;8(5-s):100-4.
- Dua K, Pabreja K, Sharma VK, Sara US, Agrawal DK. Transferosomes: Pivotal Role in Drug Delivery. *Ethiop J Health Biomed Sci*. 2009;2(1):47-52.
- Punasiya R, Joshi A, Gupta S, Punasiya J. Transferosomes-A Novel Carrier for Transdermal Drug Delivery. *Res J Pharm Dosage Form Technol*. 2010;2(2):133-8.
- Girhepunje K, Kinikar D, Pal R. Transferosomes: A Novel Carrier for Enhanced dermal Delivery of Drug. *World J Pharm Res*. 2014;3(2):2003-9.
- Dhopavkar S, Kadu P. Transferosomes-a boon for transdermal delivery. *Indo Am J Pharm Sci*. 2017;4(9):2908-19.
- Modi CD, Bharadia PD. Transferosomes: new dominants for transdermal drug delivery. *Am J Pharm Tech Res*. 2012;2(3):71-91.
- Podili C, Firoz S. A Review On Transferosomes For Transdermal Drug Delivery. *J Global Trend Pharm Sci*. 2014;5(4):2118-27.

34. Kumar AS, Deepika PK, Nagasen D, Murthy DV, Kishore VS. Transferosomes: A new vesicular carrier system in topical drug delivery. *Res J Top Cosmet Sci*. 2013;4(1):26-31.
35. Gupta A., Aggarwal G., Samita S., Arora R., Transfersomes: A Novel Vesicular Carrier for Enhanced Transdermal Delivery of Sertraline: Development, Characterization, and Performance Evaluation, *Sci Pharm*. 2012 Oct-Dec; 80(4): 1061–1080.
36. Rane BR, Gujarathi NA. Transferosomes and protransferosome: ultradeformable vesicular system. In: *Novel Approaches for Drug Delivery*. IGI Global. 2017 (pp. 149-169).
37. Thakur S, Vaddi A, Rashmitha G, Reddy S. Transferosomes. *Int Journal Pharm Res Rev*. 2013;1(1):42-59.
38. Patel Chirag J, Tyagi S, Pinkesh P, Kumar U, Jaimin P, Bharat C. Transferosomes: A Novel Technique For Transdermal Drug Delivery. *PharmaTutor*. 2012.